Skip to main navigation Skip to search Skip to main content

Amiodarone Use and All-Cause Mortality in Patients With a Continuous-Flow Left Ventricular Assist Device

  • Rakesh Gopinathannair
  • , Naga Venkata K. Pothineni
  • , Jaimin R. Trivedi
  • , Henri Roukoz
  • , Jennifer Cowger
  • , Mustafa M. Ahmed
  • , Adarsh Bhan
  • , Ashwin K. Ravichandran
  • , Geetha Bhat
  • , Amin Al Ahmad
  • , Andrea Natale
  • , Luigi Di Biase
  • , Mark S. Slaughter
  • , Dhanunjaya Lakkireddy

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Atrial and ventricular arrhythmias are commonly encountered in patients with advanced heart failure, with amiodarone being the most commonly used antiarrhythmic drug in continuous-flow left ventricular assist device (CF-LVAD) recipients. The purpose of this study was to assess the impact of amiodarone use on long-term all-cause mortality in ptients with a CF-LVAD. METHODS AND RESULTS: A retrospective multicenter study of CF-LVAD was conducted at 5 centers including all CF-LVAD implants from 2007 to 2015. Patients were stratified based on pre–CF-LVAD implant amiodarone use. Additional use of ami-odarone after CF-LVAD implantation was also evaluated. Primary outcome was all-cause mortality during long-term follow-up. Kaplan-Meier curves were used to assess survival outcomes. Multivariable Cox regression was used to identify predictors of outcomes. Propensity matching was done to address baseline differences. A total of 480 patients with a CF-LVAD (aged 58±13 years, 81% men) were included. Of these, 170 (35.4%) were on chronic amiodarone therapy at the time of CF-LVAD implant, and 310 (64.6%) were not on amiodarone. Rate of all-cause mortality over the follow-up period was 32.9% in the amiodarone group compared with 29.6% in those not on amiodarone (P=0.008). Similar results were noted in the propensity-matched group (log-rank, P=0.04). On multivariable Cox regression analysis, amiodarone use at baseline was independently associated with all-cause mortality (hazard ratio, 1.68 [95% CI, 1.1–2.5]; P=0.01). CONCLUSIONS: Amiodarone use was associated with significantly increased rates of all-cause mortality in CF-LVAD recipients. Earlier interventions for arrhythmias to avoid long-term amiodarone exposure may improve long-term outcomes in CF-LVAD recipients and needs further study.

Original languageEnglish (US)
Article numbere023762
JournalJournal of the American Heart Association
Volume11
Issue number11
DOIs
StatePublished - Jun 7 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

Keywords

  • amiodarone
  • arrhythmias
  • left ventricular assist device
  • mortality

Fingerprint

Dive into the research topics of 'Amiodarone Use and All-Cause Mortality in Patients With a Continuous-Flow Left Ventricular Assist Device'. Together they form a unique fingerprint.

Cite this